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Principles and basic concepts on the safety evaluation
of antimicrobial agents
The Japanese Society of Chemotherapy criteria for
assessment of adverse reactions and abnormal laboratory
values associated with antibacterial agents in study subjects
[1, 2] (hereinafter referred to as ‘‘JSC’s current criteria’’),
have been adopted in many clinical studies from immedi-
ately after their publication and are also cited in areas other
than antimicrobial agents. Accumulated safety data based
on the criteria have been submitted to the regulatory
authorities in Japan for marketing approval applications.
No inquiries such as uncertainty about the safety evalua-
tions in clinical studies of antimicrobial agents have been
made so far; therefore, the criteria seem to be recognized
widely, including by the regulatory authorities.
However, there is a concern that the JSC’s current cri-
teria do not ﬁt the present situation, because in recent new
drug development the results of overseas clinical studies
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have been used aggressively or global studies have been
conducted.
The Antimicrobial Agents Safety Evaluation Standards
Committee of the JSC (hereinafter, the ‘‘Committee’’) has
developed a concept of ‘‘abnormal changes in laboratory
values’’ while taking into account management of the
results of studies by overseas pharmaceutical companies.
This concept was developed for the purpose of maintaining
consistency with Western safety evaluation from a global
viewpoint. With regard to adverse events in terms of
symptoms and ﬁndings, we have summarized the infor-
mation on adverse events in clinical studies of antimicro-
bial agents approved for marketing after 2005 (see
Tables 6, 7) and discussed evaluation points for adverse
events that occurred frequently in clinical studies of anti-
microbial agents.
Abnormal changes in laboratory values
Previously, when assessing whether or not changes in
laboratory values were adverse events, we classiﬁed them
into two groups: a shift from a normal to an abnormal value
or an aggravation from the abnormal value before admin-
istration. From the perspective of maintaining consistency
with the evaluation of overseas clinical study data and in
order to be concise, however, we have established an
assessment procedure that enables each laboratory test item
to be evaluated by a Grade based on standard values for
these items. Furthermore, in consideration that the JSC’s
current criteria have been adopted in many clinical studies
and results have accumulated, we fully analyzed the
available data from clinical studies and avoided causing a
large discrepancy from current evaluation results. In par-
ticular, the assessment results when deﬁning abnormal
changes as Grade 2 or higher according to the ‘‘Common
Terminology Criteria for Adverse Events v 3.0 JCOG/
JSCO version’’ [3] (hereinafter referred to as the
‘‘CTCAE’’), which are generally found to be similar to the
JSC’s current criteria, the abnormal changes tended to be
consistent with the assessment results based on the JSC’s
current criteria. We decided that the classiﬁcation speciﬁed
in the CTCAE could be used to promote the optimum
safety evaluation of antimicrobial agents.
Details of the establishment of criteria for abnormal
changes in laboratory values have been published in the
interim report of the Japanese Society of Chemotherapy,
Antimicrobial Agents Safety Evaluation Standards Com-
mittee [4].
Symptoms/ﬁndings
Events related to ‘‘gastrointestinal disorders’’ are the most
frequent adverse events in clinical studies of antimicrobial
agents, followed by ‘‘respiratory, thoracic and mediastinal
disorders,’’ ‘‘skin and subcutaneous tissue disorders,’’
‘‘general disorders and administration site conditions,’’
‘‘infections and infestations,’’ ‘‘musculoskeletal and con-
nective tissue disorders,’’ and ‘‘nervous system disorders’’
(see Table 6). In order to individually deﬁne the severity of
each adverse event, as is done with the CTCAE, the
Committee assumed that a comprehensive analysis based
on clinical ﬁndings and epidemiological data for each
specialized ﬁeld would be necessary and that ensuring
universality would be difﬁcult. Therefore, in our report we
decided to show comprehensive criteria for the assessment
of severity, regardless of the individual symptoms and ﬁnd-
ings. This concept was also based on the idea that the opinions
of the physicians who actually take charge of clinical studies
would be appropriate for the assessment of the severity of
adverse events and their causal relationships.
Criteria for safety evaluation of laboratory values
Method for evaluation of abnormal changes
and adverse events
Criteria for abnormal changes in laboratory values are
shown in Table 1. Based on these criteria, when laboratory
values are within the range of abnormal changes, accom-
panying any adverse symptoms or ﬁndings, or possibly
resulting in them, or requiring additional tests or treatment,
they should be handled as adverse events, and the causal
relationship with the investigational drug should be assessed.
Laboratory values are known to ﬂuctuate in relation to
interindividual factors such as sex, age, and lifestyle, and
intraindividual factors such as diurnal variation, type and
timing of meals, physical exercise, body posture, and the
sexual cycle. Therefore, whether or not changes in labo-
ratory values are assessed as adverse events should be
determined by distinguishing them as physiological chan-
ges or pathological (adverse) changes, while taking com-
plete account of the background characteristics of the
subject concerned, such as underlying disease and com-
plications, and baseline values of the tests and/or changes
unique to the subject if he/she underwent periodic labora-
tory tests before study participation.
Nonetheless, there may be cases where it is not appro-
priate to simply identify individual abnormal changes in
laboratory values and determine them to be adverse events.
Considering that abnormal changes in laboratory values
involve the clinical background and adverse symptoms/
ﬁndings in the subject concerned, it is more important to
comprehensively evaluate adverse events occurring in the
subject. In other words, when no diagnostic term can be
deﬁned for an adverse event, individual abnormal changes
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in laboratory values can be handled as separate adverse
events; however, it has been found to be more appropriate
to put multiple related abnormal laboratory values together
and consider them as a symptom or ﬁnding than to deter-
mine these abnormal values to be adverse events. When
abnormal changes in laboratory values are assumed to be
adverse events, it is critical to deﬁne them as related
symptoms or ﬁndings in order to handle them as adverse
events, as exempliﬁed below.
For example, in addition to the terms ‘‘ALT (alanine ami-
notransferase) increased’’ and ‘‘AST (aspartate aminotrans-
ferase) increased,’’ whenmultiple abnormal laboratory values
related to liver function, such as ‘‘c-GT (c-glutamyl transfer-
ase)’’ and ‘‘ALP (alkaline phosphatase),’’which donot exceed
the ranges of laboratory values that should be handled as
adverse events are noted at the same time, they should be
deﬁned as ‘‘abnormal liver function tests’’.
In the present assessment, we reviewed the JSC’s current
criteria for laboratory values in clinical studies of
antimicrobial agents and we present new guidelines for
assessment criteria. In the development of antimicrobial
agents, it is not sufﬁcient to only assess the presence or
absence of abnormal changes in laboratoryvalues occurring in
each subject and to tabulate them to calculate the incidence of
abnormal changes for each laboratory test item. It is also
important to comprehensively analyze the laboratory data
collected in clinical studies, using shift tables that showed
changes in laboratory ﬁndings before and after administration
and scatter diagrams, to evaluate safety in detail as to whether
there are any laboratory test items showing characteristic
changes over time for the antimicrobial agent concerned, and
whether there are abnormal changes and changes over time
that may lead to signiﬁcant adverse reactions. In order to
achieve this, it is preferable to apply the criteria as indexes that
are not affected by any bias such as physicians’ judgment, and
to tabulate/analyze abnormal changes in laboratory values
based on certain criteria regardless of determining the changes
to be adverse events.
Table 1 Criteria for assessing abnormal changes in laboratory values as adverse events
Laboratory tests Laboratory values to be reviewed for adopting as adverse events
Red blood cell count (RBC) Male\3,500,000/mm3, female\3,200,000/mm3
Hemoglobin \10 g/dL
Hematocrit Male\35%, female\30%
White blood cell count (WBC) \3000/mm3. Increased values are not determined to be adverse events unless there is
some special reason. It may be handled as neutrophil count decreased (\1,500/mm3)
or lymphocytes decreased (\800/mm3)
Eosinophil count C500/mm3, or C10% as % of eosinophil in WBC Allergic disease should be taken into
account in the subject
Platelet count Decrease\75,000/mm3
Increase C600,000/mm3 with some symptoms, or C1,000,000/mm3
Aspartate aminotransferase (AST) Above 2.5-fold of the upper limit of the institutional standard levels
Even if the value is not above 2.5-fold, it should be considered to be handled as an
adverse event in the following cases:
Not above 2.5-fold of the institutional standard level, but the investigational drug is
likely to have greatly contributed to the change based on the range of change
Not above 2.5-fold of the institutional standard level, but there was a tendency for
increase during treatment, and the value had recovered at the time when there was no
longer the effect of the investigational drug
Alanine aminotransferase (ALT)
c-Glutamyl transferase (c-GT)
Alkaline phosphatase (ALP)
Lactate dehydrogenase (LDH)
Leucine aminopeptidase (LAP)
Creatine kinase (CK)
Total bilirubin C1.5-fold of the upper limit of the institutional standard levels
Direct bilirubin
Serum creatinine
Blood urea nitrogen (BUN)
Na Decrease B125 mEq/L, increase C155 mEq/L
K Decrease B3.2 mEq/L, increase C5.5 mEq/L
Cl Decrease B96 mEq/L, increase C115 mEq/L
Blood sugar (fasting) Decrease\55 mg/dL, increase[160 mg/dL
(For decreases, changes to\55 mg/dL are considered to be abnormal changes
regardless of whether or not the subject has had a meal)
Urinary sugar/protein Changes of C2 steps as qualitative value (-, ±, ?, ??, etc.) (when ± is included in a
qualitative value, ± should be also counted as a step)
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Points to consider for safety evaluation of laboratory
values
The Committee has created evaluation criteria for each
laboratory test item that is usually performed in clinical
studies of antimicrobial agents. The laboratory test items
speciﬁed in this report are not intended to be essential
items, though such items should be identiﬁed and selec-
ted in consideration of the characteristics of the antimi-
crobial agents to be developed. In addition, we have
determined that total cholesterol and blood triglycerides,
for which clear categories of changes could not be pre-
sented in this review, and basophil and monocyte counts,
for which the clinical signiﬁcance of their changes is
unknown, are not always required to be evaluated in
clinical studies of antimicrobial agents, unless otherwise
speciﬁed.
Based on the examination in this committee, patients
with laboratory values categorized as Grade 3 or higher
(Grade 4 or higher for Na and K) at baseline were found to
be not suitable for safety evaluation. Therefore, in princi-
ple, such patients should be excluded from enrollment in
future clinical studies. For severe hepatic dysfunction and
renal impairment, which have been stipulated in the
exclusion criteria, approximate laboratory values indicating
which candidates should be excluded from study enroll-
ment are presented in Table 2.
In previous clinical studies of antimicrobial agents,
efﬁcacy and safety were generally evaluated based on the
results at the completion of treatment (administration). In
recent years, however, concepts of test and observation
schedules in clinical studies have changed so that the
timing of primary efﬁcacy evaluation is consistent with that
in Western countries, such as assessing efﬁcacy based on
the results at the time of ‘‘test of cure visit’’ after the
completion of treatment (administration). In the future,
tests and observation will preferably be performed for
safety evaluation at the time of ‘‘test of cure visit’’ after the
completion of treatment (administration).
Criteria for safety evaluation of symptoms and ﬁndings
The deﬁnition of ‘‘adverse event’’ in clinical studies is in
accordance with ICH harmonized tripartite guideline
‘‘Clinical safety data management: deﬁnitions and stan-
dards for expedited reporting’’ [5]. Any unfavorable and
unintended sign (including an abnormal laboratory ﬁnding,
for example), symptom, or disease temporally associated
with the use of a medicinal product, whether or not con-
sidered related to the medicinal product, has to be noted.
Therefore, when identifying such symptoms or ﬁndings, all
of them should be handled as adverse events, and their
severity and causal relationship with the product should be
assessed.
In clinical studies of antimicrobial agents, the terms
‘‘diarrhea’’ and ‘‘loose stools’’ occur relatively frequently.
Consequently, the evaluation of ‘‘diarrhea’’ and ‘‘loose
stools’’ in a uniform manner is important for comparing
drugs; thus, these events should be assessed based on the
criteria below.
Evaluation of ‘‘diarrhea’’ and ‘‘loose stool’’
We deﬁned ‘‘diarrhea’’ and ‘‘loose stool’’ using the Criteria
for assessment of antimicrobial agents in pediatric clinical
study [6] as a reference to be able to apply the deﬁnitions to
clinical studies mainly in adults. ‘‘Diarrhea’’ and ‘‘loose
stool’’ should be identiﬁed and assessed based on the
deﬁnition listed in Table 3.
Severity assessment
Common assessment criteria for the severity of all adverse
events are as shown in Table 4. The assessment of seri-
ousness should be made as speciﬁed in the ‘‘Clinical safety
data management: deﬁnitions and standards for expedited
reporting’’ [5].
Assessment of a causal relationship
The assessment of a causal relationship is particularly
important information regarding an adverse event.
Currently, typical categories used for the assessment of
a causal relationship in clinical studies often include
several ranks (e.g., ‘‘related,’’ ‘‘probably related’’, ‘‘pos-
sibly related’’, and ‘‘not related’’). In the present criteria
Table 2 Approximate
laboratory values for severe
hepatic dysfunction and renal
impairment
Item Approximate laboratory values
for exclusion criteria
Liver function AST, ALT, ALP, c-GT, LDH, and LAP Above 5-fold of the upper limit
of the institutional standard levels
Total bilirubin and direct bilirubin Above 2-fold of the upper limit
of the institutional standard levelsRenal function Serum creatinine and BUN
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for safety evaluation of antimicrobial agents, a two-cate-
gory assessment is recommended, from the global per-
spective, and an assessment method is shown in Table 5.
In this Table, examples of ‘‘Information useful for
assessing the relationship’’ are presented. They should be
used as a reference for the assessment of a causal
relationship.
In some cases, a causal relationship is classiﬁed into
several categories at an early development stage. The
causal relationship can be evaluated by subdividing the
category of ‘‘related’’ speciﬁed here. In such cases, those
adverse events whose causal relationships are categorized
as so-called ‘‘unlikely’’ should be evaluated as adverse
reactions.
Conclusions
As mentioned at the beginning, we (the Committee) have
created criteria for the safety evaluation of antimicrobial
agents from the global viewpoint, taking into consideration
consistency with Western safety evaluation criteria.
Therefore, we should pay attention when adopting these
criteria after the development of a new antimicrobial agent
has been started. This is because there may be some
inconsistencies when comparing results using other these
criteria and the JSC’s current criteria, such as those related
to liver function. For instance, in the case where the safety
evaluation is made according to the JSC’s current criteria
in a phase II clinical study, and the present criteria are
adopted from a phase III study, it is important to establish
an analysis plan which enables the safety assessment to be
compared and analyzed based on both sets of criteria, and
to fully examine the appropriateness of switching the
assessment criteria in the middle of drug development
based on the results.
It is also critical to compare drugs based not only on the
safety assessment of the individual antimicrobial agents but
also based onuniﬁed assessment using the present criteria.We
hope that the present criteria will be widely employed when
conducting clinical studies of antimicrobial agents so that the
present criteria can be re-evaluated and the necessity for their
amendment in the future can be examined.
Adverse events that are likely to occur in clinical studies
of antimicrobial agents
We analyzed adverse events occurring in clinical studies of
antimicrobial agents (3 drugs from 3 companies) based on
the system organ class and preferred term of Medical
dictionary for regulatory activities terminology (MedDRA)
J/V9.0.
Table 3 Deﬁnitions of ‘‘diarrhea’’ and ‘‘loose stool’’
Normal stool Stool having a smooth
surface and a shape
similar to sausage
Stool having clear margins,
being soft and semisolid
and having a shape like
a coiled snake
Loose stool Thick stool without a shape
like a coiled snake
Diarrhea
Muddy stool Muddy stool without
margins and shape
Watery stool Watery stool
without lumps
Table 4 Assessment of the severity of adverse events
Severity Criteria
Mild An event that does not interfere with
activities of daily living (when abnormal
changes in laboratory values are evaluated
individually) e.g., abnormal changes in
laboratory values without adverse
symptoms correspond to this criterion
Moderate An event that interferes with activities of
daily living, including the case where the
investigational treatment is discontinued.
When the treatment has been terminated by
a patient’s judgment, the event should be
assessed while taking account of the
symptom or ﬁnding concerned and the
patient’s condition (when abnormal
changes in laboratory values are evaluated
individually), e.g., abnormal changes in
laboratory values which need follow-up
examination and also treatment, or which
accompany adverse symptoms interfering
with activities of daily living
Severe An event that prevents activities of daily
living, those events which do not meet the
above criteria for mild and moderate events
When the concerned symptom or ﬁnding is present at baseline and has
worsened, and it is assessed as an adverse event, its severity should
not be determined based on a difference in the condition from base-
line but based on the condition at the time when the case is judged to
be an adverse event
When disease (including suspected disease) can be identiﬁed based on
multiple related abnormal changes in laboratory values and the events
are deﬁned as other related disease, it should not be automatically
determined to be ‘‘severe,’’ but the severity of the concerned disease
should be comprehensively assessed
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Table 5 Criteria for assessment of a causal relationship
Causal
relationship
Criteria
Related The adverse event whose relationship to the
investigational agent is temporally appropriate can be
explained as a known reaction or pharmacological
action of the investigational drug or its analogue
Factors other than the investigational drug (e.g., primary
disease, underlying disease, complication, and
concomitant medication) should be fully examined. The
causal relationship to the investigational drug should be
determined as ‘‘related’’ unless the relationship is
deﬁnite
Not related The concerned adverse event is determined to be not late-
onset, and a relationship between the investigational
treatment and adverse event is temporally inappropriate
The event is caused by factors other than the
investigational drug (e.g., primary disease, underlying
disease, complication, and concomitant medication),
and the relationship to the investigational drug can be
almost certainly or completely denied
Information useful for assessing the relationship
Adverse event occurred
Presence or absence of overdosing or long-term treatment
Whether the drug was administered prior to the onset of adverse
event
Presence or absence of concomitant medications or previous
treatment drugs
Presence or absence of local reaction (e.g., use of injection, suppository,
and sublingual formulations)
Whether the event disappeared after treatment discontinuation
Whether concomitant medications were discontinued at the same time
Past history
Whether a similar event occurred in the past (regardless of drug
treatment)
Whether the event is associated with drugs in the same class
Whether the event is associated with drugs in other classes
Findings
Whether the temporal interval between drug administration
and the onset of the event is appropriate
Whether the concerned event occurs spontaneously in rare cases
Whether the event has been known to possibly occur in relation
to treated disease or existing illness
Whether the concerned event tends to develop in relation to treated
disease or concurrent illness
Whether non-drug treatment is associated (e.g., puncture and surgery)
Whether there are any other associated factors (e.g., alcohol
consumption, other habits, and environment)
Whether the concerned event has been found in past clinical studies
or in drugs in the same class
Whether the concerned event can be explained based
on the biological properties of the investigational drug
or drugs in the same class
Whether the concerned event has been reported for pharmacologically
similar drugs
Whether the concerned event has been reported for concomitant
medications or previous treatment drugs
Whether the concerned event is possibly caused by drug interaction
Table 6 Types and numbers of adverse events that have occurred in
clinical studies of antimicrobial agents (MedDRA J/V9.0)
System organ class No. of types
Gastrointestinal disorders 40
Respiratory, thoracic, and mediastinal disorders 22
Skin and subcutaneous tissue disorders 21
General disorders and administration-site conditions 16
Infections and infestations 15
Musculoskeletal and connective tissue disorders 15
Nervous system disorders 14
Injury, poisoning, and procedural complications 9
Psychiatric disorders 8
Renal and urinary disorders 8
Eye disorders 6
Cardiac disorders 6
Ear and labyrinth disorders 5
Vascular disorders 4
Blood and lymphatic system disorders 3
Reproductive system and breast disorders 3
Metabolism and nutrition disorders 2
Immune system disorders 1
Table 7 Adverse events that have occurred in clinical studies of
antimicrobial agents (MedDRA J/V9.0)
System organ class Code Preferred term
Infections and
infestations
10022000 Inﬂuenza
10001076 Acute sinusitis
10019948 Herpes simplex
10019974 Herpes zoster
10020377 Hordeolum
10028810 Nasopharyngitis
10034835 Pharyngitis
10035664 Pneumonia
10043873 Tinea pedis
10044008 Tonsillitis
10046306 Upper respiratory tract
infection
10046898 Vaginal candidiasis
10060889 Tinea infection
10062352 Respiratory tract
infection
10009899 Pseudomembranous
colitis
Blood and lymphatic
system disorders
10013442 Disseminated
intravascular
coagulation
10025188 Lymphadenitis
10025197 Lymphadenopathy
Immune system
disorders
10002817 Antiphospholipid
syndrome
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Table 7 continued
System organ class Code Preferred term
Metabolism and
nutrition disorders
10002646 Anorexia
10061428 Decreased appetite
Psychiatric disorders 10002855 Anxiety
10012378 Depression
10010893 Conversion disorder
10022437 Insomnia
10029333 Neurosis
10054196 Affect lability
10038743 Restlessness
10061284 Mental disorder
Nervous system
disorders
10008118 Cerebral infarction
10013496 Disturbance in attention
10013573 Dizziness
10013578 Dizziness postural
10013887 Dysarthria
10013911 Dysgeusia
10019211 Headache
10020937 Hypoesthesia
10033775 Paresthesia
10034701 Peroneal nerve palsy
10021118 Hypotonia
10041349 Somnolence
10042772 Syncope
10044565 Tremor
Eye disorders 10000173 Abnormal sensation in eye
10015993 Eyelid edema
10047513 Vision blurred
10064132 Conjunctivochalasis
10007739 Cataract
10030041 Ocular hyperemia
Ear and labyrinth
disorders
10011878 Deafness
10043882 Tinnitus
10047348 Vertigo positional
10052137 Ear discomfort
Cardiac disorders 10011703 Cyanosis
10033557 Palpitations
10040752 Sinus tachycardia
10003658 Atrial ﬁbrillation
10007554 Cardiac failure
10015856 Extrasystoles
Vascular disorders 10016825 Flushing
10033546 Pallor
10040560 Shock
10020772 Hypertension
10060800 Hot ﬂush
Table 7 continued
System organ class Code Preferred term
Respiratory, thoracic,
and mediastinal
disorders
10003553 Asthma
10011224 Cough
10013968 Dyspnea
10014962 Eosinophilic pneumonia
10015090 Epistaxis
10018964 Hemoptysis
10022611 Interstitial lung disease
10028735 Nasal congestion
10034844 Pharyngolaryngeal
pain
10035598 Pleural effusion
10035759 Pneumothorax
10036790 Productive cough
10037383 Pulmonary ﬁbrosis
10037410 Pulmonary infarction
10037423 Pulmonary edema
10038695 Respiratory failure
10039085 Rhinitis allergic
10039101 Rhinorrhea
10041232 Sneezing
10057009 Pharyngeal erythema
10061877 Obstructive airways
disorder
10068319 Oropharyngeal pain
Skin and subcutaneous
tissue disorders
10000496 Acne
10009866 Cold sweat
10011985 Decubitus ulcer
10012431 Dermatitis
10012442 Dermatitis contact
10013687 Drug eruption
10014184 Eczema
10014190 Eczema asteatotic
10015150 Erythema
10019343 Heat rash
10020642 Hyperhidrosis
10033551 Palmar erythema
10034972 Photosensitivity reaction
10037087 Pruritus
10037549 Purpura
10037844 Rash
10037868 Rash maculo-papular
10037876 Rash papular
10039793 Seborrheic dermatitis
10046735 Urticaria
10052576 Pruritus generalized
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Table 7 continued
System organ class Code Preferred term
Gastrointestinal
disorders
10000059 Abdominal discomfort
10000060 Abdominal distension
10000081 Abdominal pain
10000084 Abdominal pain
lower
10000087 Abdominal pain
upper
10000097 Abdominal
tenderness
10008417 Cheilitis
10010774 Constipation
10012735 Diarrhea
10013781 Dry mouth
10013946 Dyspepsia
10016101 Feces hard
10016766 Flatulence
10017367 Frequent bowel
movements
10017853 Gastritis
10017944 Gastrointestinal
disorder
10018286 Gingival pain
10018292 Gingivitis
10018386 Glossitis
10018388 Glossodynia
10018836 Hematochezia
10027141 Melena
10020601 Hyperchlorhydria
10023003 Irritable bowel
syndrome
10024552 Lip dry
10028813 Nausea
10030973 Oral discomfort
10031009 Oral pain
10034023 Parotid gland
enlargement
10039408 Salivary gland
enlargement
10039424 Salivary hypersecretion
10042101 Stomach discomfort
10042128 Stomatitis
10043951 Tongue disorder
10047700 Vomiting
10051992 Lip erosion
10053155 Epigastric discomfort
10056819 Gastric disorder
10057371 Hypoesthesia oral
10057372 Paresthesia oral
Table 7 continued
System organ class Code Preferred term
Musculoskeletal and
connective tissue
disorders
10003239 Arthralgia
10003988 Back pain
10006811 Bursitis
10008690 Chondrocalcinosis
pyrophosphate
10016717 Fistula
10016750 Flank pain
10028334 Muscle spasms
10028372 Muscular weakness
10028411 Myalgia
10028836 Neck pain
10033425 Pain in extremity
10040617 Shoulder pain
10049816 Muscle tightness
10052904 Musculoskeletal
stiffness
10061224 Limb discomfort
Renal and urinary
disorders
10011730 Cylindruria
10013990 Dysuria
10018867 Hematuria
10036018 Pollakiuria
10038435 Renal failure
10046543 Urinary incontinence
10049710 Urethral hemorrhage
10060695 Residual urine
Reproductive system
and breast disorders
10004073 Balanitis
10027304 Menopausal
symptoms
10037093 Pruritus genital
General disorders and
administration-site
conditions
10003549 Asthenia
10008469 Chest discomfort
10008479 Chest pain
10008531 Chills
10011906 Death
10016322 Feeling abnormal
10016334 Feeling hot
10017577 Gait disturbance
10022067 Injection-site
hemorrhage
10022086 Injection-site pain
10022090 Injection-site
phlebitis
10025482 Malaise
10030124 Edema peripheral
10034568 Peripheral coldness
10037660 Pyrexia
10043458 Thirst
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As shown in Table 6, in the clinical studies of antimi-
crobial agents, events related to ‘‘gastrointestinal disorders’’
are most frequently followed by ‘‘respiratory, thoracic and
mediastinal disorders,’’ ‘‘skin and subcutaneous tissue dis-
orders,’’ ‘‘general disorders and administration site condi-
tions,’’ ‘‘infections and infestations,’’ ‘‘musculoskeletal and
connective tissue disorders’’, and ‘‘nervous system
disorders’’.
Individual adverse events that occurred in clinical
studies of antimicrobial agents are shown in Table 7.
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Table 7 continued
System organ class Code Preferred term
Injury, poisoning, and
procedural
complications
10003986 Back injury
10016173 Fall
10023229 Joint sprain
10037765 Radiation pneumonitis
10039117 Rib fracture
10041569 Spinal fracture
10049796 Excoriation
10049947 Lumbar vertebral
fracture
10050584 Contusion
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